IMNM
Companies
NASDAQ
Immunome Inc.
Health Care
$8.74
-$1.88 (-17.75%)
Price Chart
Overview
About IMNM
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.
Market Cap
$911.5M
Volume
9.7M
Avg. Volume
9.8M
P/E Ratio
-2.7793105
Dividend Yield
0.00%
Employees
52.0
Company Information
Risk & Correlation Analysis
Market Correlation
0.78
Moderate Correlation
Volatility
High (0.75)
Relative to market
Macro Factor Sensitivities
Interest Rates
Low Sensitivity
Inflation
High Sensitivity
GDP Growth
Low Sensitivity
Liquidity
High Sensitivity
Commodity Prices
Low Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, IMNM shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Key Statistics
Market Cap$911.5M
Volume9.7M
P/E Ratio-2.78
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
May 13, 2025Related Securities
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025